Regulatory Achievement Overview
Mesoblast has obtained seven years of orphan-drug exclusive approval from FDA for RYONCIL® (remestemcel-L) in treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients.
Exclusivity Specifications
| Protection Type | Duration | Expiration | Coverage |
|---|---|---|---|
| Orphan-Drug Exclusivity | 7 years | 2032 | MSC products |
| Biologic Exclusivity | 12 years | 2036 | Biosimilar prevention |
| Patent Protection | Extended | 2044 | IP rights |
Market Impact
Technical Achievement
Key elements include:
. Regulatory approval
. Extended protection
. Manufacturing capability
. Clinical validation
. Market exclusivity
. Therapeutic innovation
Strategic Benefits
The approval provides:
. Market protection
. Commercial advantage
. Treatment access
. Innovation recognition
. Development pathway
. Growth platform
More Info
250515 Mesoblast receives seven-year FDA orphan-drug exclusivity for RYONCIL®, strengthening market position in cellular medicinesDownload
✨ Support Our Mission ✨
Help us continue building tools that simplify complexity!
Every contribution fuels new features and improvements
Thank you for being part of our journey! 🚀
Contact Us
